Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors

@inproceedings{Brydy2009ObservationalSO,
  title={Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors},
  author={Marianne Bryd{\o}y and Jan Oldenburg and Olbj{\o}rn H Klepp and Roy Martin Bremnes and Erik Andreas Wist and Tore Wentzel-Larsen and Erik R. Hauge and Olav Dahl and Sophie D Fossa},
  booktitle={Journal of the National Cancer Institute},
  year={2009}
}
BACKGROUND Sensory neuropathy (paresthesias), tinnitus, hearing impairment, and Raynaud phenomena are side effects of cisplatin-based chemotherapy used to treat testicular cancer patients. We assessed the long-term occurrence of these side effects among testicular cancer survivors according to the treatment they received. METHODS A total of 1814 men who were treated for unilateral testicular cancer in Norway during 1980-1994 were invited to participate in a national multicenter follow-up… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

Longitudinal long-term outcomes after treatment for testicular cancer

VIEW 27 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS

Cancer Neurology in Clinical Practice

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

VIEW 2 EXCERPTS

Long-term toxicity of the treatment for germ cell-cancer. A review.

VIEW 1 EXCERPT
CITES BACKGROUND

Testicular Cancer: Epidemiology, Diagnosis, and Management.

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 66 REFERENCES

Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma.